AstraZeneca, Durvalumab
AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%
The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.
AstraZeneca Pharma shares rally 13%, hit 52-week high after receiving nod for cancer drug Durvalumab
The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs).
AstraZeneca Pharma gets nod to sell immunotherapy drug Durvalumab; stock surges
This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.
Lung cancer drug: AstraZeneca India wins CDSCO nod for Durvalumab for specified additional indication
Bengaluru: AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central
AstraZeneca Pharma Surges on CDSO Approval for Durvalumab in India
AstraZeneca Pharma India has received approval from the CDSO for the import, sale, and distribution of Durvalumab.
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
Key Takeaways A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.The trial included over 700 patients with inoperable or metastatic breast cancer.
Cure Today9h
Imfinzi Improves Survival Outcomes in Subgroups of Patients with LS-SCLC
Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of ...
Indian shares likely to open at record highs
Indian shares were set to open at record highs on Tuesday, tracking gains in Asian peers, and extending their rally after the ...
Medscape7d
'One of the Most Impactful' ESMO Studies: Durvalumab in Muscle-Invasive Bladder Cancer
BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...
moneycontrol.com21h
Stock Radar: ONGC, Reliance, PNB, AstraZeneca, GR Infra, BGR Energy, Arkade Developers, Coal India in focus on Tuesday
The company has received approval to import, sell, and distribute Durvalumab Solution for infusion (Imfinzi) from the ...
Sensex, Nifty Marginally Higher As Metal Stocks Rally On China Stimulus Hopes
Metal stocks traded higher, with JSW Steel, Hindalco and Tata Steel climbing 2-3 percent on China stimulus hopes. Reliance Power jumped 5 percent after its board approved a prefer ...
Medscape10d
No DFS Benefit With Adjuvant Durvalumab in Early NSCLC
The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in ...